Collaboration combines Ethris’ proprietary technology platforms with DZIF’s infectious disease research expertise to advance mRNA-based vaccines across a broad range of pathogens
Ethris GmbH, a clinical-stage biotechnology company focused on advanced RNA-based medicines and vaccines, has entered into a new research partnership with the German Center for Infection Research, known as DZIF. The collaboration is aimed at advancing mRNA-based vaccines for both the prevention and treatment of infectious diseases. By bringing together Ethris’ proprietary and clinically tested mRNA platforms with DZIF’s extensive translational research capabilities, the initiative targets a wide range of pathogens, including viral, bacterial, and parasitic infections.
Health Technology Insights: Corus Orthodontists Secures C$20 Million Equity Investment
Dr. Carsten Rudolph, Chief Executive Officer of Ethris, explained that while early mRNA vaccines reshaped infectious disease prevention, they only marked the beginning of what the technology can achieve. He noted that the joint effort with DZIF is focused on developing more advanced vaccines that offer broader and longer-lasting protection. According to him, Ethris is working to enhance mRNA stability and precision delivery so future vaccines can adapt more easily to emerging variants and be deployed across diverse healthcare environments. He emphasized that the long-term vision is to shift vaccination strategies from reacting to outbreaks toward building sustained preparedness.
Health Technology Insights: AACN Teams with Xapify to Digitize Competence Framework
Dr. Klaus Schwamborn, Head of Vaccine Development at DZIF, highlighted that the organization’s core objective is to turn high-quality infection research into practical medical solutions, particularly in areas where current vaccines or therapies are insufficient. He stated that partnering with Ethris provides access to a sophisticated mRNA platform that can be applied to new pathogens, antimicrobial resistance challenges, and populations with weaker immune responses, while also helping promising vaccine concepts move more quickly toward clinical testing.
As part of the agreement, DZIF will gain access to Ethris’ Stabilized Non-Immunogenic mRNA and Stabilized NanoParticle lipid delivery technologies. Vaccine materials will be produced by Ethris’ manufacturing partners, including Patheon UK Limited, a Thermo Fisher Scientific company, and Evonik Operations GmbH. These platforms are designed to deliver stable, low-immunogenic mRNA through multiple administration routes and are supported by industrial-scale manufacturing that meets quality standards for preclinical and clinical development. Ethris brings more than ten years of experience in stabilized mRNA therapeutics, with its lead candidate ETH47 currently advancing through Phase 2a clinical development.
DZIF brings together over 700 researchers and clinicians from 35 institutions across Germany, all working to develop vaccines, diagnostics, and treatments for infectious diseases. Its research portfolio covers areas such as emerging infections, tuberculosis, hepatitis, HIV, malaria, gastrointestinal infections, and diseases affecting immunocompromised patients, with a strong focus on translating scientific discoveries into real-world clinical applications.
Health Technology Insights: SEQSTER Expands Partnership with Praxis Precision Medicines
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
